# Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

> **NCT05659251** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 48 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- Neoadjuvant Therapy

## Interventions

- **COMBINATION_PRODUCT:** Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
- **PROCEDURE:** Esophagectomy
- **OTHER:** sample

## Key facts

- **NCT ID:** NCT05659251
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659251, "Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05659251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*